(¦hÛ¦h4¤é¥[·sªÀ¹q)¥[®³¤j½Ã¥Í³¡©¾§i»¡¡M°ª¦åÀ£±wªÌ¤£n¦X¨ÖªA¥Î´XºØ°¦åÀ£ÃĪ«¡M¨º·|¼W¥[°·±d·ÀI¡C½Ã¥Í³¡«ü¥X¡MµÇ¯À§í¨î¾¯(renin inhibitor)ªü§Q§JÛ(aliskiren)¡M¦pªG»P¥t¥~¨âÃþÃĪ«¤¤¥ô¦ó¤@ºØ²V¦X¨Ï¥Î¡M³£·|±a¨Ó°·±d·ÀI¡C¥t¥~¨âÃþÃĪ«¬O¦åºÞ¦¬ÁY¯ÀÂà¤Æ»Ã¯À§í¨î¾¯(angiotensin-converting enzyme inhibitors)©Î¦åºÞºò±i¯À¨üÅéªýÂ_¾¯(angiotensin receptor blockers)¡C³o¨ÇÃĪ«ªº¥ô¦ó¦X¨Ö¨Ï¥Î¡M±N·|¼W¥[§C¦åÀ£¡N°ª¦å¹[»PµÇŦ°ÝÃDªº·ÀI¡C ½Ã¥Í³¡ªºÁn©ú«ü¥X¡M¿}§¿¯f©MµÇŦ¯e¯fªº±wªÌ¡M¤£À³±Nªü§Q§JÛ»P¨ä¥L¥ô¦óÃþÃĪ«²V¦X¨Ï¥Î¡M¨º·|¼W¥[¤¤·©Î©ü³Ö·ÀI¡C¥Á²³¥i¬d¸ß½Ã¥Í³¡ºô¯¸¤Wªº¦W³æ¡M¨ä¤¤¦C©úþ¨Ç²£«~¤¤§t¦³³o¨ÇÃĪ«¦¨¤À¡C
|
|
|